Abstract
Advances in our understanding of hepatic fibrosis have provoked great excitement over the prospect of effective antifibrotic therapy. This Viewpoint looks at how far the field has advanced, what the remaining obstacles are, and whether antifibrotic therapy might soon become a clinical reality for patients with chronic liver disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Nature Clinical Practice Gastroenterology & Hepatology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
